Before a clinical trial can even have a hope of succeeding, it needs one thing: patients. Faced with a limited amount of recruitment time and even smaller budgets, companies often fall short of reaching their recruitment goals.
In yesterday’s session, "Technology-Based Solutions and Social Media Strategies for Patient Recruitment, Enrollment, and Retention," John Burnett, CEO and Founder of JAPA Associates, and Dennis Upah, Executive Vice President of HealthCentral, discussed how social media can help recruit more patients in a less expensive and faster manner than other tactics used in the past. The session touched on how to develop effective marketing and communication by leveraging technology for patient recruitment and how to determine key considerations in your strategy with different therapeutic areas. Attendees also learned about relatively new FDA regulations regarding social recruitment.
Another topic addressed during the session was best practices of the use of technology in patient recruitment abroad versus in the United States. Research indicates that there are similar conversion rates for online recruitment throughout the world. Although some companies might want to avoid using social media at all in the United States, doing so would mean missing out on one of the best ways to reach its targeted demographic.
Besides offering a more efficient way of recruiting patients whether in the United States or abroad, social media allows companies to find the specific type of patient they are looking for.
“By their very nature, the vast majority of clinical trials are seeking an increasingly narrow audience of potential participants. Continuing, therefore, to rely on a broadcast medium to find them no longer makes sense,” Upah said in an interview with Applied Clinical Trials.
Patients are starting to form their own communities online in order to share information about their specific medical conditions. Pharmaceutical companies can reach out to these groups through informational websites, advertising on social media, and using social media itself. And just because social media may be cheaper, don’t think it means less work.
“An online community has to be nurtured over time, and a variety of tactics need to be tried as each trial in each disease state is different,” Upah said. “It may take a tremendous amount of time to work their way through regulatory issues and build a community that they can create trust with.”
Companies also have to learn how to handle other specific social media issues such as dealing with adverse event reporting in a timely manner, and portraying accurate medical data without destroying the free flow of communication that a social forum should encompass.
In addition, CROs should be aware of the different regulatory guidelines that govern social media. For instance, most regulations currently are for companies that host their own forums rather than for companies that place advertisements on an already-existing site. Thus, because CROs are often given a recruitment period of months and not years, it is often preferable for a company to partner with a health community rather than create a unique forum. Upah stressed the notion that building a relationship was key to receiving the best results regardless of whether or not a CRO forms its own social media group or advertises on an existing one.
“You would not throw a cocktail party without any friends and just expect people to show up. First, you would nurture a relationship with those friends, make them feel safe and trusted, ensure that both you and they feel there is something of value within the relationship, and only then would you throw the party,” Upah said. “Leveraging an online community is the same way.”
Social Media Challenges and Solutions
Before a clinical trial can even have a hope of succeeding, it needs one thing: patients. Faced with a limited amount of recruitment time and even smaller budgets, companies often fall short of reaching their recruitment goals.
In yesterday’s session, "Technology-Based Solutions and Social Media Strategies for Patient Recruitment, Enrollment, and Retention," John Burnett, CEO and Founder of JAPA Associates, and Dennis Upah, Executive Vice President of HealthCentral, discussed how social media can help recruit more patients in a less expensive and faster manner than other tactics used in the past. The session touched on how to develop effective marketing and communication by leveraging technology for patient recruitment and how to determine key considerations in your strategy with different therapeutic areas. Attendees also learned about relatively new FDA regulations regarding social recruitment.
Another topic addressed during the session was best practices of the use of technology in patient recruitment abroad versus in the United States. Research indicates that there are similar conversion rates for online recruitment throughout the world. Although some companies might want to avoid using social media at all in the United States, doing so would mean missing out on one of the best ways to reach its targeted demographic.
Besides offering a more efficient way of recruiting patients whether in the United States or abroad, social media allows companies to find the specific type of patient they are looking for.
“By their very nature, the vast majority of clinical trials are seeking an increasingly narrow audience of potential participants. Continuing, therefore, to rely on a broadcast medium to find them no longer makes sense,” Upah said in an interview with Applied Clinical Trials.
Patients are starting to form their own communities online in order to share information about their specific medical conditions. Pharmaceutical companies can reach out to these groups through informational websites, advertising on social media, and using social media itself. And just because social media may be cheaper, don’t think it means less work.
“An online community has to be nurtured over time, and a variety of tactics need to be tried as each trial in each disease state is different,” Upah said. “It may take a tremendous amount of time to work their way through regulatory issues and build a community that they can create trust with.”
Companies also have to learn how to handle other specific social media issues such as dealing with adverse event reporting in a timely manner, and portraying accurate medical data without destroying the free flow of communication that a social forum should encompass.
In addition, CROs should be aware of the different regulatory guidelines that govern social media. For instance, most regulations currently are for companies that host their own forums rather than for companies that place advertisements on an already-existing site. Thus, because CROs are often given a recruitment period of months and not years, it is often preferable for a company to partner with a health community rather than create a unique forum. Upah stressed the notion that building a relationship was key to receiving the best results regardless of whether or not a CRO forms its own social media group or advertises on an existing one.
“You would not throw a cocktail party without any friends and just expect people to show up. First, you would nurture a relationship with those friends, make them feel safe and trusted, ensure that both you and they feel there is something of value within the relationship, and only then would you throw the party,” Upah said. “Leveraging an online community is the same way.”
ASTRO Trial Shows SC Tremfya Provides Significant Clinical Benefits in Moderately to Severely Active Ulcerative Colitis
Tremfya could become the first IL-23 inhibitor with fully subcutaneous induction and maintenance options in the treatment of moderately to severely active ulcerative colitis.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Final Analysis of CheckMate -816 Trial Shows Opdivo Plus Chemotherapy Boosts Overall Survival in Resectable NSCLC
The final analysis of the Phase III CheckMate -816 trial confirmed a statistically significant overall survival benefit for patients with resectable non-small cell lung cancer treated with neoadjuvant Opdivo (nivolumab) plus chemotherapy.
Reaching Diverse Patient Populations With Personalized Treatment Methods
Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Turning Uncertainty into Opportunity: Smarter Clinical Asset Evaluation Powered by Causal Machine Learning
Machine learning can help investors dive deeper into trial data to evaluate the true potential of an asset and uncover new hidden opportunities.
Five-Year POETYK PSO Trial Results Show Sustained Efficacy, Safety with Sotyktu for Moderate-to-Severe Plaque Psoriasis
Five-year data from the POETYK PSO long-term extension trial confirm the sustained efficacy and safety of Sotyktu (deucravacitinib) for moderate-to-severe plaque psoriasis, with patients maintaining high clinical response rates and no new safety concerns identified.
ASTRO Trial Shows SC Tremfya Provides Significant Clinical Benefits in Moderately to Severely Active Ulcerative Colitis
Tremfya could become the first IL-23 inhibitor with fully subcutaneous induction and maintenance options in the treatment of moderately to severely active ulcerative colitis.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Final Analysis of CheckMate -816 Trial Shows Opdivo Plus Chemotherapy Boosts Overall Survival in Resectable NSCLC
The final analysis of the Phase III CheckMate -816 trial confirmed a statistically significant overall survival benefit for patients with resectable non-small cell lung cancer treated with neoadjuvant Opdivo (nivolumab) plus chemotherapy.
Reaching Diverse Patient Populations With Personalized Treatment Methods
Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Turning Uncertainty into Opportunity: Smarter Clinical Asset Evaluation Powered by Causal Machine Learning
Machine learning can help investors dive deeper into trial data to evaluate the true potential of an asset and uncover new hidden opportunities.
Five-Year POETYK PSO Trial Results Show Sustained Efficacy, Safety with Sotyktu for Moderate-to-Severe Plaque Psoriasis
Five-year data from the POETYK PSO long-term extension trial confirm the sustained efficacy and safety of Sotyktu (deucravacitinib) for moderate-to-severe plaque psoriasis, with patients maintaining high clinical response rates and no new safety concerns identified.